NICE was the first EU HTA body to provide their assessment of Kymriah for ALL, publishing their opin...
Read moreCanadians pay too much for prescription drugs – and that means far too many go without the medicin...
Read moreSpeaking at the international pharma conference, NICE’s chief executive Sir Andrew Dillon struck a...
Read moreAdults with lymphoma will not be able to access Novartis’ CAR-T therapy Kymriah on the NHS in Scot...
Read moreConclusion: Blincyto has significant clinical benefits, but that further evidence on cost-effective...
Read moreNHS England continues to develop its pricing and reimbursement expertise by appointing Blake Dark, a...
Read moreIf the French government is able to deliver, pharmaceutical companies can look forward to potentiall...
Read moreCancer drug prices are rising rapidly, and profit margins for pharmaceutical companies reach upwards...
Read moreDetermine the potential price and reimbursement status of a prospective business development asset.
Read moreUnderstanding payer value and evidence requirements to secure pricing and reimbursement for an oncol...
Read more